These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17513827)

  • 1. EGFR expression and mutational analysis as a predictive test.
    Raz DJ; Jablons DM
    J Clin Oncol; 2007 May; 25(15):2144; author reply 2144-5. PubMed ID: 17513827
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Costa DB; Kobayashi S
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR mutations and sensitivity to gefitinib.
    Sorscher SM
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15371587
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.
    Brandão EP; Pantarotto MG; Cruz M
    J Thorac Oncol; 2012 Nov; 7(11):e32. PubMed ID: 23070249
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
    Shepherd FA
    J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
    Shepherd FA; Tsao MS
    J Clin Oncol; 2006 Mar; 24(7):1219-20; author reply 1220-1. PubMed ID: 16505443
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.
    van der Wekken AJ; Stigt JA; A't Hart N
    J Thorac Oncol; 2012 Aug; 7(8):e8. PubMed ID: 22797155
    [No Abstract]   [Full Text] [Related]  

  • 11. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.
    Yatabe Y; Pao W; Jett JR
    J Thorac Oncol; 2012 May; 7(5):775-6. PubMed ID: 22722783
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
    Normanno N; Di Maio M; Perrone F; Campiglio M
    J Clin Oncol; 2004 May; 22(10):2035-6; author reply 2036-7. PubMed ID: 15143103
    [No Abstract]   [Full Text] [Related]  

  • 14. EGFR mutations and sensitivity to gefitinib.
    Rossi G; Marchioni A; Longo L
    N Engl J Med; 2004 Sep; 351(12):1260-1; author reply 1260-1. PubMed ID: 15376351
    [No Abstract]   [Full Text] [Related]  

  • 15. Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
    Jänne PA
    J Clin Oncol; 2006 Jul; 24(21):3319-21. PubMed ID: 16785470
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
    Sequist LV; Haber DA; Lynch TJ
    Clin Cancer Res; 2005 Aug; 11(16):5668-70. PubMed ID: 16115901
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
    J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib plus docetaxel in non-small-cell lung cancer.
    Zalcman G; Bergot E
    Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217981
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
    Shih JY; Gow CH; Yu CJ; Yang CH; Chang YL; Tsai MF; Hsu YC; Chen KY; Su WP; Yang PC
    Int J Cancer; 2006 Feb; 118(4):963-9. PubMed ID: 16152581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.